SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases

Nazanin Zamani-Siahkali¹, Seyed Ali Mirshahvalad², Abolfazl Farbod¹, Ghasemali Divband³, Christian Pirich⁴, Patrick Veit-Haibach⁵, Gary Cook⁶, Mohsen Beheshti⁷

Affiliations

¹ Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria; Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran.
² Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria; Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Canada.
³ Department of Nuclear Medicine, Jam Hospital, Tehran, Iran.
⁴ Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria.
⁵ Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Canada.
⁶ Cancer Imaging Department, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
⁷ Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria. Electronic address: m.beheshti@salk.at.

PMID: 38172001
DOI: 10.1053/j.semnuclmed.2023.11.005

Free article

Review

SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases

Nazanin Zamani-Siahkali et al. Semin Nucl Med. 2024 May.

Free article

. 2024 May;54(3):356-370.

doi: 10.1053/j.semnuclmed.2023.11.005. Epub 2024 Jan 3.

Authors

Nazanin Zamani-Siahkali¹, Seyed Ali Mirshahvalad², Abolfazl Farbod¹, Ghasemali Divband³, Christian Pirich⁴, Patrick Veit-Haibach⁵, Gary Cook⁶, Mohsen Beheshti⁷

Affiliations

¹ Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria; Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran.
² Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria; Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Canada.
³ Department of Nuclear Medicine, Jam Hospital, Tehran, Iran.
⁴ Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria.
⁵ Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Canada.
⁶ Cancer Imaging Department, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
⁷ Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria. Electronic address: m.beheshti@salk.at.

PMID: 38172001
DOI: 10.1053/j.semnuclmed.2023.11.005

Abstract

Recent developments in hybrid SPECT/CT systems and the use of cadmium-zinc-telluride (CZT) detectors have improved the diagnostic accuracy of bone scintigraphy. These advancements have paved the way for novel quantitative approaches to accurate and reproducible treatment monitoring of bone metastases. PET/CT imaging using [¹⁸F]F-FDG and [¹⁸F]F-NaF have shown promising clinical utility in bone metastases assessment and monitoring response to therapy and prediction of treatment response in a broad range of malignancies. Additionally, specific tumor-targeting tracers like [^99mTc]Tc-PSMA, [⁶⁸Ga]Ga-PSMA, or [¹¹C]C- or [¹⁸F]F-Choline revealed high diagnostic performance for early assessment and prognostication of bone metastases, particularly in prostate cancer. PET/MRI appears highly accurate imaging modality, but has associated limitations notably, limited availability, more complex logistics and high installation costs. Advances in artificial intelligence (Al) seem to improve the accuracy of imaging modalities and provide an assistant role in the evaluation of treatment response of bone metastases.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mohsen Beheshti reports a relationship with Novartis Pharma GmbH that includes: board membership and consulting or advisory. Christian Pirich reports a relationship with Novartis Pharma GmbH that includes: board membership and consulting or advisory.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases

Affiliations

SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous